comparemela.com

Latest Breaking News On - Mariana oncology inc - Page 1 : comparemela.com

Goldman Sachs Says Buy European Pharma Stocks Touting Innovation

Goldman Sachs Says Buy European Pharma Stocks Touting Innovation
bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.

United-kingdom
Switzerland
Denmark
Singapore
Germany
Swiss
British
German
Danish
James-quigley
Thyagu-adinarayan
Novo-nordisk

Asahi Kasei to Buy Swedish Biotech for Rare Disease Drug

Asahi Kasei to Buy Swedish Biotech for Rare Disease Drug
bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.

Stockholm
Sweden
Swedish
Asahi-kasei
Natsuko-katsuki
Van-lanschot-kempen
Health-partners
Mariana-oncology-inc
Human-immunology-biosciences-inc
Novartis
Asahi-kasei-corp
Biogen-inc

Novartis to Buy Mariana Oncology, Paying $1 Billion Upfront

Novartis to Buy Mariana Oncology, Paying $1 Billion Upfront
bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.

Massachusetts
United-states
Watertown
Switzerland
Swiss
Bloomberg-novartis
Novartis
Mariana-oncology-inc
Mariana-oncology

Novartis Buys Mariana Oncology, Paying $1B Upfront

Mariana is a clinical-stage biotech with a portfolio of experimental drugs to treat a range of solid tumors, such as breast, prostate and lung cancer.

Switzerland
Swiss
Mariana-oncology-inc
Novartis
Mariana-oncology

Radioactive taste: Mariana glows for Novartis in $1.75B deal

Novartis AG is bolstering its radioligand arsenal with the takeout of Mariana Oncology Inc. for $1 billion up front and as much as $750 million in potential milestone payments. Watertown, Mass.-based Mariana has developed peptide-based radiopharmaceuticals targeting solid tumors. The company’s lead program, MC-339, is a radioligand approach to small-cell lung cancer, due to enter the clinic later this year.

Mariana-oncology-inc
Mariana-oncology
Novartis-ag
Mariana-oncology-inc
Radiopharmaceuticals
Solid-tumors
Mc-339
Small-cell-lung-cancer
Radioligand-therapy
Bioworld
Deals-andm-amp-a

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.